| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | PD-0332991 | FIMM | pan-cancer | AAC | -0.061 | 0.7 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.065 | 0.7 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | -0.023 | 0.7 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |